NICE
NICE recommends Janssen’s Darzalex myeloma combo
March 12, 2019Manufacturing and Production Janssen, NICE, Velcade, darzalex, myeloma
Britain’s cost effectiveness body NICE have recommended Janssen Pharmaceutical’s Darzalex in combination with Velcade and dexamethasone (DVd), for use within …
Scottish Medicines Consortium rejects Novartis’ CAR T therapy Kymriah
March 12, 2019Manufacturing and Production Kymriah, NICE, Novartis, SMC, Scotland, UK
Scotland’s cost effectiveness body has refused to fund Novartis’ CAR T therapy Kymriah for adult patients with lymphoma. The Scottish …
Roche’s Perjeta secures NICE approval in adjuvant HER2+ metastatic breast cancer
February 15, 2019Medical Communications, Sales and Marketing NICE, Perjeta, Roche, pharma
NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of …
NICE joins forces with Canadian peer to offer scientific advice to the pharma industry
February 6, 2019Research and Development, Sales and Marketing CADTH, Canada, NICE, UK, pharma
NICE has announced a collaboration with its Canadian counterpart, the Canadian Agency for Drugs and Technology in Health (CADTH), with …
Novartis’ CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma
February 1, 2019Medical Communications, Sales and Marketing CAR-T, Cancer, Kymriah, NICE, Novartis, lymphoma, pharma
NICE has announced another momentous decision for lymphoma patients in England and Wales:, recommending Novartis’ chimeric antigen receptor T cell …
NICE recommends Pierre Fabre’s Braftovi in BRAF V600-mutated advanced melanoma
January 21, 2019Sales and Marketing Braftovi, Cancer, NICE, Pierre Fabre, UK, melanoma, pharma
Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by …
Abbvie’s chronic lymphocytic leukaemia drug Venclytxo scores greenlight from NICE
January 18, 2019Medical Communications, Sales and Marketing AbbVie, NHS, NICE, Venclyxto, leukaemia, pharma
A new recommendation from NICE means that thousands of patients in England and Wales will be able to receive Abbvie’s …
Eli Lilly’s Verzenios scores NICE recommendation for advanced breast cancer
January 17, 2019Sales and Marketing Cancer, Eli Lilly, NICE, Verzenios, breast cancer, pharma
Breast cancer patients in England and Wales now have access to another treatment option, as NICE announces its recommendation of …
NICE rejects Novartis’ Aimovig migraine injection for NHS use
January 10, 2019Sales and Marketing Aimovig, NICE, Novartis, migraine, pharma
It’s disappointing news for Novartis as NICE revealed that it had decided not to recommend Aimovig (erenumab) for routine NHS …
NICE recommends AstraZeneca’s Fasenra as third treatment option for severe asthma
January 4, 2019Medical Communications, Sales and Marketing AstraZeneca, Fasenra, NHS, NICE, UK, asthma, pharma
It’s good news for both asthma patients and AstraZeneca after UK drug watchdog NICE saw fit to recommend the drugmaker’s …
NICE recommends Lenvima as alternative first-line therapy for advanced liver cancer
December 19, 2018Research and Development, Sales and Marketing Lenvima, NICE, UK, liver cancer, pharma
UK drug watchdog NICE has revealed that it has recommended Eisai’s Lenvima (lenvatinib) for use on the NHS in England …
NICE give go-ahead to Gilead’s Yescarta for adults with lymphoma
December 7, 2018Medical Communications Cancer, Cost, Gilead, NHS, NICE, Yescarta, access
The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma. Gilead’s treatment will …
NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis
December 4, 2018Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis
UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …
Cancer drug access for NHS patients is slowing, ICR reports
December 4, 2018Manufacturing and Production, Research and Development, Sales and Marketing Cancer, ICR, Institute of Cancer Research, NHS, NICE, UK, pharma
A new report from the Institute of Cancer Research (ICR) has indicated that NHS patients in the UK are suffering …
Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund
November 30, 2018Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
